Piramal Pharma gets EIR with VAI for USA manufacturing facility
The receipt of said EIR marks successful closure of the inspection
Piramal Pharma has received Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) from U.S. Food and Drug Administration (USFDA) for its manufacturing facility located at Lexington, (Kentucky, USA). The receipt of said EIR marks successful closure of the inspection.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
